Prostate Cancer Transrectal HIFU Ablation: Detection of Local Recurrences Using T2-weighted and Dynamic Contrast-enhanced MRI

Overview

Journal Eur Radiol

Specialty Radiology

Date 2009 Aug 20

PMID 19690866

Citations 31

Authors

Olivier Rouviere

Nicolas Girouin

Ludivine Glas

Alexandre Ben Cheikh

Albert Gelet

Florence Mege-Lechevallier

Muriel Rabilloud

Jean-Yves Chapelon

Denis Lyonnet

Affiliations

Soon will be listed here.

Abstract

The objective was to evaluate T2-weighted (T2w) and dynamic contrast-enhanced (DCE) MRI in detecting local cancer recurrences after prostate high-intensity focused ultrasound (HIFU) ablation. Fifty-nine patients with biochemical recurrence after prostate HIFU ablation underwent T2-weighted and DCE MRI before transrectal biopsy. For each patient, biopsies were performed by two operators: operator 1 (blinded to MR results) performed random and colour Doppler-guided biopsies ("routine biopsies"); operator 2 obtained up to three cores per suspicious lesion on MRI ("targeted biopsies"). Seventy-seven suspicious lesions were detected on DCE images (n = 52), T2w images (n = 2) or both (n = 23). Forty patients and 41 MR lesions were positive at biopsy. Of the 36 remaining MR lesions, 20 contained viable benign glands. Targeted biopsy detected more cancers than routine biopsy (36 versus 27 patients, p = 0.0523). The mean percentages of positive cores per patient and of tumour invasion of the cores were significantly higher for targeted biopsies (p < 0.0001). The odds ratios of the probability of finding viable cancer and viable prostate tissue (benign or malignant) at targeted versus routine biopsy were respectively 3.35 (95% CI 3.05-3.64) and 1.38 (95% CI 1.13-1.63). MRI combining T2-weighted and DCE images is a promising method for guiding post-HIFU biopsy towards areas containing recurrent cancer and viable prostate tissue.

Citing Articles

Salvage external beam radiotherapy after HIFU failure in localized prostate cancer: A single institution experience.

Di Lalla V, Elakshar S, Anidjar M, Tolba M, Hassan T, Bahoric B Front Oncol. 2022; 12:1028858.

PMID: 36408146 PMC: 9669274. DOI: 10.3389/fonc.2022.1028858.

Identification of Denatured Biological Tissues Based on Compressed Sensing and Improved Multiscale Dispersion Entropy during HIFU Treatment.

Liu B, Wang R, Peng Z, Qin L Entropy (Basel). 2020; 22(9).

PMID: 33286712 PMC: 7597216. DOI: 10.3390/e22090944.

Role of multiparametric prostate MRI in the management of prostate cancer.

OConnor L, Lebastchi A, Horuz R, Rastinehad A, Siddiqui M, Grummet J World J Urol. 2020; 39(3):651-659.

PMID: 32583039 DOI: 10.1007/s00345-020-03310-z.

Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound.

Ghafoor S, Becker A, Stocker D, Barth B, Eberli D, Donati O Abdom Radiol (NY). 2020; 45(11):3882-3895.

PMID: 32447414 DOI: 10.1007/s00261-020-02577-5.

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.

van der Poel H, Grivas N, van Leeuwen P, Heijmink S, Schoots I World J Urol. 2019; 37(8):1485-1490.

PMID: 30788590 DOI: 10.1007/s00345-019-02677-y.

References

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M . Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008; 54(3):589-600. DOI: 10.1016/j.eururo.2007.12.034. View

Kim J, Hong S, Choi Y, Park S, Ahn H, Kim C . Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005; 22(5):639-46. DOI: 10.1002/jmri.20431. View

Kim C, Park B, Lee H, Kim S, Kim E . MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008; 190(5):1180-6. DOI: 10.2214/AJR.07.2924. View

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach 3rd M . Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60(4):1047-55. DOI: 10.1016/j.ijrobp.2004.05.015. View

Coakley F, Teh H, Qayyum A, Swanson M, Lu Y, Roach 3rd M . Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004; 233(2):441-8. DOI: 10.1148/radiol.2332032086. View

Gelet A, Chapelon J, Margonari J, Theillere Y, Gorry F, Souchon R . High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol. 1993; 23 Suppl 1:44-7. DOI: 10.1159/000474679. View

Blana A, Walter B, Rogenhofer S, Wieland W . High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology. 2004; 63(2):297-300. DOI: 10.1016/j.urology.2003.09.020. View

Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal J . Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?. Eur Radiol. 2006; 17(6):1498-509. DOI: 10.1007/s00330-006-0478-9. View

Rouviere O, Mege-Lechevallier F, Chapelon J, Gelet A, Bouvier R, Boutitie F . Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur Urol. 2006; 50(3):490-7. DOI: 10.1016/j.eururo.2005.12.046. View

10.

Gelet A, Chapelon J, Margonari J, Theillere Y, Gorry F, Cathignol D . Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol. 1993; 7(3):249-53. DOI: 10.1089/end.1993.7.249. View

11.

Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon J . Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings. Urology. 2004; 63(5):922-7. DOI: 10.1016/j.urology.2003.12.017. View

12.

Gelet A, Chapelon J, Poissonnier L, Bouvier R, Rouviere O, Curiel L . Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology. 2004; 63(4):625-9. DOI: 10.1016/j.urology.2004.01.002. View

13.

Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T . Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol. 2006; 13(3):228-33. DOI: 10.1111/j.1442-2042.2006.01272.x. View

14.

Cheikh A, Girouin N, Colombel M, Marechal J, Gelet A, Bissery A . Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol. 2008; 19(3):770-8. DOI: 10.1007/s00330-008-1190-8. View

15.

Lim H, Kim J, Kim K, Cho K . Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study. Radiology. 2008; 250(1):145-51. DOI: 10.1148/radiol.2501080207. View

16.

Chapelon J, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A . In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res. 1992; 52(22):6353-7. View

17.

Poissonnier L, Chapelon J, Rouviere O, Curiel L, Bouvier R, Martin X . Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2006; 51(2):381-7. DOI: 10.1016/j.eururo.2006.04.012. View

18.

Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mege-Lechevallier F, Gelet A, Chapelon J . [MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results]. J Radiol. 2008; 89(5 Pt 1):571-7. DOI: 10.1016/s0221-0363(08)71483-5. View

19.

Haider M, Chung P, Sweet J, Toi A, Jhaveri K, Menard C . Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 70(2):425-30. DOI: 10.1016/j.ijrobp.2007.06.029. View

20.

Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon J, Lyonnet D . Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol. 2007; 63(3):317-27. DOI: 10.1016/j.ejrad.2007.06.026. View